跳转至内容
Merck

T6394

Sigma-Aldrich

噻吗洛尔 马来酸盐

≥98% (TLC), powder

别名:

(S)-3-[3-(叔丁基氨基)-2-羟基丙氧基]-4-吗啉基-1,2,5-噻二唑马来酸盐 马来酸盐, (S)-马来酸噻吗洛尔

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C13H24N4O3S · C4H4O4
CAS号:
分子量:
432.49
EC號碼:
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

品質等級

化驗

≥98% (TLC)

形狀

powder

光學活性

[α]25/D -5.4°, c = 4.9 in 1 M HCl(lit.)

顏色

white to off-white

mp

202-203 °C (lit.)

溶解度

H2O: soluble
ethanol: soluble

&epsilon ;(消光係數)

8,700 at 294 nm at 1 M

起源

Merck & Co., Inc., Kenilworth, NJ, U.S.

SMILES 字串

[H]\C(=C(/[H])C(O)=O)C(O)=O.CC(C)(C)NC[C@H](O)COc1nsnc1N2CCOCC2

InChI

1S/C13H24N4O3S.C4H4O4/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17;5-3(6)1-2-4(7)8/h10,14,18H,4-9H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t10-;/m0./s1

InChI 密鑰

WLRMANUAADYWEA-NWASOUNVSA-N

基因資訊

正在寻找类似产品? 访问 产品对比指南

應用

Timolol maleate has been used as an adrenergic β-blocker for evaluating cardiovascular functions in mice5. It has also been used for evaluating the uptake of 86Rb+ in rat cardiomyocytes6.

生化/生理作用

Timolol maleate is a class II anti-arrhythmic agent that functions as a non-selective β-adrenoceptor antagonist, a vasodilator and an anti-glaucoma agent. Studies have reported that timolol maleate can be used for the treatment of infantile hemangioma (IH)7.

特點和優勢

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

準備報告

Timolol maleate is soluble in ethanol and water.

象形圖

Health hazardExclamation mark

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral - Repr. 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

個人防護裝備

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Ajith Chakkittakandiyil et al.
Pediatric dermatology, 29(1), 28-31 (2011-12-14)
Therapeutic options for superficial infantile hemangiomas (IH) are limited. Recently, timolol maleate gel, a topical nonselective beta-blocker, has been reported as a potentially effective treatment for superficial IH. This study is an extension of a previously published pilot study designed
Ahmad Shojaei et al.
American journal of ophthalmology, 154(5), 790-798 (2012-09-01)
To compare the effects of timolol on refractive outcomes in eyes with myopic regression after laser in situ keratomileusis (LASIK) with a control-matched group. Prospective, randomized, parallel-controlled, double-masked clinical trial. A computer-generated randomization list based on random block permutation (length
G C Chiou et al.
Journal of ocular pharmacology, 8(3), 183-190 (1992-01-01)
An ocular hypertensive rabbit eye model was used to study the effect of L- and D-timolol on retinal and choroidal blood flow. Ocular hypertension was induced artificially by raising the intraocular pressure to 40 mmHg which reduced the ocular blood
Jin-Wei Cheng et al.
PloS one, 7(9), e45079-e45079 (2012-10-03)
The first goal of medical therapy in glaucoma is to reduce intraocular pressure (IOP), and the fixed-combination medications are needed to achieve sufficiently low target IOP. The aim of this systematic review and meta-analysis is to evaluate IOP-lowering effect of
A Tomidokoro et al.
Current eye research, 18(5), 381-390 (1999-06-18)
To evaluate the effects of topical carteolol or timolol on tissue circulation in the iris and posterior choroid. After a topical instillation of 20 microl of 2% carteolol, 0.5% timolol, or physiological saline (for control) into one eye, and physiological

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门